Cyclophosphamide-Associated Uroepithelial Toxicity
Authors: Ronnier J. Aviles, Stacey A. Vlahakis, Peter L. Elkin
Journal: Annals of Internal Medicine (1999)

Letters5 October 1999Cyclophosphamide-Associated Uroepithelial ToxicityRonnier J. Aviles, MD, Stacey A. Vlahakis, MD, and Peter L. Elkin, MDRonnier J. Aviles, MDMayo Clinic and Mayo Foundation; Rochester, MN 55905 (Aviles)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Vlahakis)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Elkin)Search for more papers by this author, Stacey A. Vlahakis, MDMayo Clinic and Mayo Foundation; Rochester, MN 55905 (Aviles)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Vlahakis)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Elkin)Search for more papers by this author, and Peter L. Elkin, MDMayo Clinic and Mayo Foundation; Rochester, MN 55905 (Aviles)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Vlahakis)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Elkin)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-7-199910050-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The urologic complications of cyclophosphamide therapy often limit its use (1). We describe what we believe to be the first case in the literature of isolated upper urinary tract toxicity. This toxicity occurred after a cumulative oral cyclophosphamide 1.4 g, which is lower than any reported to date.A 72-year-old woman with a 7-year history of Wegener granulomatosis presented with gross hematuria and dysuria of 1 week's duration. She received cyclophosphamide (1.4 g) over 2 weeks as treatment for relapse of the granulomatosis.On admission, the patient appeared acutely ill but was hemodynamically stable. Urinalysis showed gross ...References1. Watson NA, Notley RG. Urological complications of cyclophosphamide. Br J Urol. 1973;45:606-9. CrossrefMedlineGoogle Scholar2. Philips FS, Sternberg SS, Cronin AP, Vidal PM. Cyclophosphamide and urinary bladder toxicity. Cancer Res. 1961;21:1577-89. MedlineGoogle Scholar3. Cox PJ. Cyclophosphamide cystitis—identification of acrolein as the causative agent. Biochem Pharmacol. 1979;28:2045-9. CrossrefMedlineGoogle Scholar4. Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, et al . Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med. 1979;91:221-3. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Aviles)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Vlahakis)Mayo Clinic and Mayo Foundation; Rochester, MN 55905 (Elkin) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOn the Death of House Officers Faith Fitzgerald and T. Jock Murray Metrics Cited ByCyclophosphamideDRUGS USED IN CANCER CHEMOTHERAPYGLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGSCyclophosphamideDrugs acting on the immune systemCyclophosphamide 5 October 1999Volume 131, Issue 7Page: 549KeywordsAngiographyCyclophosphamideHemorrhageNecrosisPelvisToxicityUlcersUltrasound imagingUreterWegener granulomatosis Issue Published: 5 October 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...